S12 Ep28: Ivonescimab Improves PFS vs Pembrolizumab in Advanced PD-L1+ NSCLC: With Xiuning Le, MD, PhD
In today’s episode, supported by Summit Therapeutics, we had the pleasure of speaking with Xiuning Le, MD, PhD, about the use of ivonescimab (SMT112) in patients with PD-L1–positive non–small cell lung cancer (NSCLC). Dr Le is an associate professor in the Department of Thoracic/Head and Neck Medical Oncology in the Division of Internal Medicine at The University of Texas MD Anderson Cancer Center in Houston.
The phase 3 HARMONi-2 trial (NCT05499390) investigated ivonescimab vs pembrolizumab (Keytruda) in patients with locally advanced or metastatic, PD-L1–positive NSCLC without sensitizing…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.